Medicare Enrolled

Dr. Andrew Mak, M.D.

Hematology & Oncology · Amarillo, TX
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
1751 WALLACE BLVD, Amarillo, TX 79106
8062124673
Registered in NPPES since 2015
NPI: 1306227376 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mak from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mak? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mak

Dr. Andrew Mak is a hematology & oncology specialist in Amarillo, TX, with 11 years of NPI registration. Based on federal Medicare data, Dr. Mak performed 388 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Mak received a total of $4,356 from 40 pharmaceutical and/or device companies across 105 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mak is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 11 years of NPI registration ▲ 388 Medicare services $4,356 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
388
Medicare services
Bottom 25% in TX for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
Not available
Unique patients (not deduplicated)
$88
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
148 $69 $230
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
148 $102 $310
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
55 $90 $350
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
22 $97 $305
New patient office visit, complex (60-74 min) 15 $126 $445
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.

Industry Payment Transparency

Open Payments through 2024 ↗
$4,356
Total received (2020-2024)
Avg $871/year across 5 years
Top 46% in TX for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
105
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$953
2023
$1,282
2022
$855
2021
$776
2020
$489

Payments by company (2024)

Incyte Corporation
$85
Astellas Pharma US Inc
$61
Genentech USA, Inc.
$58
Blueprint Medicines Corporation
$57
Daiichi Sankyo Inc.
$56
PFIZER INC.
$51
Merck Sharp & Dohme LLC
$51
Novartis Pharmaceuticals Corporation
$50
Alexion Pharmaceuticals, Inc.
$46
Celgene Corporation
$45
Gilead Sciences, Inc.
$42
BeiGene USA, Inc.
$38
ABBVIE INC.
$35
TerSera Therapeutics LLC
$34
ARRAY BIOPHARMA INC
$31
Agios Pharmaceuticals, Inc.
$23
E.R. Squibb & Sons, L.L.C.
$22
Genmab U.S., Inc.
$21
SERVIER PHARMACEUTICALS LLC
$21
Takeda Pharmaceuticals U.S.A., Inc.
$21
MorphoSys, US Inc.
$20
Lilly USA, LLC
$18
SpringWorks Therapeutics, Inc.
$18
Bayer Healthcare Pharmaceuticals Inc.
$18
Aveo Pharmaceuticals, Inc.
$17
AstraZeneca Pharmaceuticals LP
$16
Top 3 companies account for 21.4% of 2024 payments
All-time payments by company (2020-2024) ›
Incyte Corporation
$1,007
AstraZeneca Pharmaceuticals LP
$386
Astellas Pharma US Inc
$243
Janssen Biotech, Inc.
$235
Myriad Genetic Laboratories, Inc.
$218
Daiichi Sankyo Inc.
$198
Amgen Inc.
$178
Celgene Corporation
$170
Novartis Pharmaceuticals Corporation
$164
Kite Pharma, Inc.
$136
Eisai Inc.
$120
E.R. Squibb & Sons, L.L.C.
$119
Janssen Scientific Affairs, LLC
$106
EISAI INC.
$104
Genmab U.S., Inc.
$101
Merck Sharp & Dohme LLC
$82
Blueprint Medicines Corporation
$71
Takeda Pharmaceuticals U.S.A., Inc.
$66
PFIZER INC.
$65
Gilead Sciences, Inc.
$62
Genentech USA, Inc.
$58
ABBVIE INC.
$52
Alexion Pharmaceuticals, Inc.
$46
BeiGene USA, Inc.
$38
TerSera Therapeutics LLC
$34
ARRAY BIOPHARMA INC
$31
Dendreon Pharmaceuticals LLC
$28
Agios Pharmaceuticals, Inc.
$23
Acrotech Biopharma LLC
$23
SERVIER PHARMACEUTICALS LLC
$21
Seagen Inc.
$20
MorphoSys, US Inc.
$20
Lilly USA, LLC
$18
SpringWorks Therapeutics, Inc.
$18
Bayer Healthcare Pharmaceuticals Inc.
$18
Bayer HealthCare Pharmaceuticals Inc.
$18
Aveo Pharmaceuticals, Inc.
$17
CTI BioPharma Corp.
$15
Rigel Pharmaceuticals, Inc.
$14
ADC Therapeutics America, Inc.
$14
Top 3 companies account for 37.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Alecensa · BELEODAQ · BOSULIF · BRUKINSA · CALQUENCE · Columvi · DARZALEX · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · FOTIVDA · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · LUMAKRAS · LYNPARZA · Lenvima · MONJUVI · Nplate · Nubeqa · OGSIVEO · ONUREG · OPDIVO · PEMAZYRE · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · PROVENGE · PYRUKYND · Padcev · REBLOZYL · RYBREVANT · Stivarga · TAGRISSO · TASIGNA · TIVDAK · Tavalisse · Tivdak · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Vanflyta · Venclexta · Vonjo · Vyloy · XALKORI · Yescarta · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a hematology & oncology specialist in Amarillo?
Compare hematology & oncology specialists in the Amarillo area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists in nearby ZIP areas
10
County median income
$50,448
Nearest hospital to ZIP centroid (approximate)
NORTHWEST TEXAS HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Mak is a clinical cardiology specialist, with moderate Medicare volume.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Mak experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Mak performed 148 office visit, established patient (30-39 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Mak receive payments from pharmaceutical companies?
Yes. Dr. Mak received a total of $4,356 from 40 companies across 105 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mak's costs compare to other hematology & oncology specialists in Amarillo?
Dr. Mak's average Medicare payment per service is $88. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mak) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →